By SPC News Staff
Today, the FDA granted a new indication for sofosbuvir-velpatasvir (SOF/VEL; Epclusa, Gilead) to treat hepatitis C virus (HCV) in children aged 6 years and older or weighing at least 37 pounds (17 kg) with any of the six HCV genotypes without cirrhosis or with mild cirrhosis.
SOF/VEL, the first pan-genotypic, protease inhibitor–free regimen, in combination with ribavirin is indicated for the treatment of pediatric patients aged 6 years and older or weighing at least